342 related articles for article (PubMed ID: 33176725)
1. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.
Huebner H; Kurbacher CM; Kuesters G; Hartkopf AD; Lux MP; Huober J; Volz B; Taran FA; Overkamp F; Tesch H; Häberle L; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Ruebner M; Untch M; Fasching PA; Janni W; Fehm TN; Kolberg HC; Wallwiener D; Brucker SY; Schneeweiss A; Ettl J
BMC Cancer; 2020 Nov; 20(1):1091. PubMed ID: 33176725
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Sequist LV; Gray JE; Harb WA; Lopez-Chavez A; Doebele RC; Modiano MR; Jackman DM; Baggstrom MQ; Atmaca A; Felip E; Provencio M; Cobo M; Adiwijaya B; Kuesters G; Kamoun WS; Andreas K; Pipas JM; Santillana S; Cho BC; Park K; Shepherd FA
Oncologist; 2019 Aug; 24(8):1095-1102. PubMed ID: 30975923
[TBL] [Abstract][Full Text] [Related]
3. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
Mendell J; Freeman DJ; Feng W; Hettmann T; Schneider M; Blum S; Ruhe J; Bange J; Nakamaru K; Chen S; Tsuchihashi Z; von Pawel J; Copigneaux C; Beckman RA
EBioMedicine; 2015 Mar; 2(3):264-71. PubMed ID: 26137564
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
Liu JF; Ray-Coquard I; Selle F; Poveda AM; Cibula D; Hirte H; Hilpert F; Raspagliesi F; Gladieff L; Harter P; Siena S; Del Campo JM; Tabah-Fisch I; Pearlberg J; Moyo V; Riahi K; Nering R; Kubasek W; Adiwijaya B; Czibere A; Naumann RW; Coleman RL; Vergote I; MacBeath G; Pujade-Lauraine E
J Clin Oncol; 2016 Dec; 34(36):4345-4353. PubMed ID: 27998236
[TBL] [Abstract][Full Text] [Related]
5. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
6. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
Hartkopf AD; Huober J; Volz B; Nabieva N; Taran FA; Schwitulla J; Overkamp F; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lux MP; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Wimberger P; Hielscher C; Geberth M; Fersis N; Abenhardt W; Kurbacher C; Wuerstlein R; Thomssen C; Untch M; Fasching PA; Janni W; Fehm TN; Wallwiener D; Brucker SY; Schneeweiss A
Breast; 2018 Feb; 37():42-51. PubMed ID: 29100043
[TBL] [Abstract][Full Text] [Related]
7. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
Schoeberl B; Kudla A; Masson K; Kalra A; Curley M; Finn G; Pace E; Harms B; Kim J; Kearns J; Fulgham A; Burenkova O; Grantcharova V; Yarar D; Paragas V; Fitzgerald J; Wainszelbaum M; West K; Mathews S; Nering R; Adiwijaya B; Garcia G; Kubasek B; Moyo V; Czibere A; Nielsen UB; MacBeath G
NPJ Syst Biol Appl; 2017; 3():16034. PubMed ID: 28725482
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
Menendez JA; Mehmi I; Lupu R
J Clin Oncol; 2006 Aug; 24(23):3735-46. PubMed ID: 16847284
[TBL] [Abstract][Full Text] [Related]
9. Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.
Meulendijks D; Jacob W; Voest EE; Mau-Sorensen M; Martinez-Garcia M; Taus A; Fleitas T; Cervantes A; Lolkema MP; Langenberg MHG; De Jonge MJ; Sleijfer S; Han JY; Calles A; Felip E; Kim SW; Schellens JHM; Wilson S; Thomas M; Ceppi M; Meneses-Lorente G; James I; Vega-Harring S; Dua R; Nguyen M; Steiner L; Adessi C; Michielin F; Bossenmaier B; Weisser M; Lassen UN
Clin Cancer Res; 2017 Sep; 23(18):5406-5415. PubMed ID: 28600476
[No Abstract] [Full Text] [Related]
10. Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines.
Hijazi MM; Thompson EW; Tang C; Coopman P; Torri JA; Yang D; Mueller SC; Lupu R
Int J Oncol; 2000 Oct; 17(4):629-41. PubMed ID: 10995872
[TBL] [Abstract][Full Text] [Related]
11. Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.
Yarar D; Lahdenranta J; Kubasek W; Nielsen UB; MacBeath G
Mol Cancer Ther; 2015 Sep; 14(9):2072-80. PubMed ID: 26116360
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
13. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
Shi X; Xu L; Yu J; Fang X
Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
[TBL] [Abstract][Full Text] [Related]
14. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
Razumienko EJ; Scollard DA; Reilly RM
J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
[TBL] [Abstract][Full Text] [Related]
15. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry.
Lux MP; Nabieva N; Hartkopf AD; Huober J; Volz B; Taran FA; Overkamp F; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Wimberger P; Hielscher C; Geberth M; Abenhardt W; Kurbacher C; Wuerstlein R; Thomssen C; Untch M; Fasching PA; Janni W; Fehm TN; Wallwiener D; Schneeweiss A; Brucker SY
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30577662
[TBL] [Abstract][Full Text] [Related]
16. Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients.
Hein A; Gass P; Walter CB; Taran FA; Hartkopf A; Overkamp F; Kolberg HC; Hadji P; Tesch H; Ettl J; Wuerstlein R; Lounsbury D; Lux MP; Lüftner D; Wallwiener M; Müller V; Belleville E; Janni W; Fehm TN; Wallwiener D; Ganslandt T; Ruebner M; Beckmann MW; Schneeweiss A; Fasching PA; Brucker SY
Breast Cancer Res Treat; 2016 Jul; 158(1):59-65. PubMed ID: 27283834
[TBL] [Abstract][Full Text] [Related]
17. Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer.
Papadimitropoulou A; Vellon L; Atlas E; Steen TV; Cuyàs E; Verdura S; Espinoza I; Menendez JA; Lupu R
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086721
[TBL] [Abstract][Full Text] [Related]
18. Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer - Results from the prospective German TMK cohort study.
Fietz T; Tesch H; Rauh J; Boller E; Kruggel L; Jänicke M; Marschner N;
Breast; 2017 Aug; 34():122-130. PubMed ID: 28586735
[TBL] [Abstract][Full Text] [Related]
19. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
20. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
Müller V; Hein A; Hartkopf AD; Fasching PA; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lüftner D; Wallwiener M; Beckmann MW; Schneeweiss A; Belleville E; Uhrig S; Wimberger P; Hielscher C; Meyer J; Wurmthaler LA; Kurbacher CM; Wuerstlein R; Untch M; Janni W; Taran FA; Lux MP; Wallwiener D; Brucker SY; Fehm TN; Michel LL
Eur J Cancer; 2022 Sep; 172():13-21. PubMed ID: 35728342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
